ArticlePLoS neglected tropical diseases2008
An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study.
Article in PLoS neglected tropical diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 88 citations in OpenAlex.
- Molecular characterization and functional effect on canie peripheral blood mononuclear cells of phosphoglycerate kinase from Echinococcus granulosus.Parasitology research · 2026Article
- Oral administration of recombinant Bacillus subtilis spores induces protective immunity against Echinococcus granulosus infection in dogs.Parasites & vectors · 2025Article
- Cocktail vaccine induces immunoprotection and modulates the fecal microbiota in dogs against Echinococcus granulosus infection.NPJ vaccines · 2025Article
- Correction: An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: A pilot study.PLoS neglected tropical diseases · 2025Article
- Development of the antigenic recombinant tropomyosin of Echinococcus granulosus in a bacterial system as a vaccinal candidate against canine echinococcosis.Revista peruana de medicina experimental y salud publica · 2025Article
- Echinococcus granulosus sensu lato control measures: a specific focus on vaccines for both definitive and intermediate hosts.Parasites & vectors · 2024Review
- Evaluation of protective immune responses induced by DNA vaccines encodingFrontiers in veterinary science · 2024Article
- Protective efficacy of six recombinant proteins as vaccine candidates against Echinococcus granulosus in dogs.PLoS neglected tropical diseases · 2023Article
- What about the Cytoskeletal and Related Proteins of Tapeworms in the Host's Immune Response? An Integrative Overview.Pathogens (Basel, Switzerland) · 2023Review
- The RecombinantFrontiers in immunology · 2022Article
- Salmonella-induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model.Current research in immunology · 2022Article
- Molecular characterization and immune protection of the 3-hydroxyacyl-CoA dehydrogenase gene in Echinococcus granulosus.Parasites & vectors · 2021Article
- Molecular Characterization of a Tetraspanin TSP11 Gene inFrontiers in veterinary science · 2021Article
- Use of Veterinary Vaccines for Livestock as a Strategy to Control Foodborne Parasitic Diseases.Frontiers in cellular and infection microbiology · 2020Review
- Article
- Echinococcosis: Advances in the 21st Century.Clinical microbiology reviews · 2019Review
- Mouse intestinal microbiota reduction favors local intestinal immunity triggered by antigens displayed in Bacillus subtilis biofilm.Microbial cell factories · 2018Article
- Bacillus subtilis spore with surface display of paramyosin from Clonorchis sinensis potentializes a promising oral vaccine candidate.Parasites & vectors · 2018Article
- Oral Application of Recombinant Bacillus subtilis Spores to Dogs Results in a Humoral Response against Specific Echinococcus granulosus Paramyosin and Tropomyosin Antigens.Infection and immunity · 2018Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dogs are the main source of human cystic echinococcosis. An oral vaccine would be an important contribution to control programs in endemic countries. We conducted two parallel experimental trials in Morocco and Tunisia of a new oral vaccine candidate against Echinococcus granulosus in 28 dogs. The vaccine was prepared using two recombinant proteins from adult worms, a tropomyosin (EgTrp) and a fibrillar protein similar to paramyosin (EgA31), cloned and expressed in a live attenuated strain of Salmonella enterica serovar typhimurium.In each country, five dogs were vaccinated with the associated EgA31 and EgTrp; three dogs received only the vector Salmonella; and six dogs were used as different controls. The vaccinated dogs received two oral doses of the vaccine 21 d apart, and were challenged 20 d later with 75,000 living protoscoleces. The controls were challenged under the same conditions. All dogs were sacrificed 26-29 d postchallenge, before the appearance of eggs, for safety reasons.We studied the histological responses to both the vaccine and control at the level of the duodenum, the natural localization of the cestode. Here we show a significant decrease of parasite burden in vaccinated dogs (70% to 80%) and a slower development rate in all remaining worms. The Salmonella vaccine EgA31-EgTrp demonstrated a high efficacy against E. granulosus promoting its potential role in reducing transmission to humans and animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.